The U.S. Food and Drug Administration is investigating the drug Vytorin for a possible cancer risk.
Vytorin is a combination of the cholesterol-lowering drugs Zocor and Zetia.
As reported by WebMD, 4.1% of patients taking Vytorin as part of a recent clinical trial died of some form of cancer. That's compared to 2.5% of the patients involved in the study who took an inactive placebo and also died from cancer.
The FDA says people taking Vytorin should not stop taking the drug but administration officials do recommend that patients speak with their doctors.
Manufacturers of Vytorin say they have complied with the FDA's requests.